RealFeedApp Moderna CEO expects FDA approval in 2027
Successful intismeran trial results confirm mRNA potential in oncology. The company plans to continue research in rare diseases and autoimmune disorders.
- Field
- medicine and diagnostics
- What they did
- Moderna completed Phase 3 trials of its personalized cancer vaccine, intismeran, which showed effectiveness in treating melanoma.
- Why it matters
- This could help the FDA approve the vaccine by 2027, allowing its expansion to other cancer types and autoimmune disorders.
#moderna#mrna#cancer#clinical trial#intismeran
